AstraZeneca on Tuesday announced it has completed the acquisition of the rights to Actavis’ branded respiratory business in the U.S. and Canada.
After the acquisition is completed, AstraZeneca will pay Actavis $600 million and future royalties over a certain revenue threshold. AstraZeneca also paid $100 million for multiple contractual consents and approvals.
The tactical transaction bolsters AstraZeneca’s respiratory franchise worldwide. The move builds on the 2014 acquisition of Almirall’s respiratory portfolio by extending AstraZeneca’s development and commercialization rights into the U.S. for Tudorza Pressair and Duaklir Genuair.
Tudorza Pressair is a long-acting muscarinic antagonist and Duaklir Genuai is a combination of a fixed dose of aclidinium with formoterol long-acting beta agonist in a dry powder inhaler to treat chronic obstructive pulmonary disease.
AstraZeneca is a global biopharmaceutical business that focuses on the development, commercialization and discover of prescription medicines, mostly for the treatment of cardiovascular, metabolic, inflammation, autoimmune, oncoology, respiratory, neuroscience and infection diseases.